Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (521-530 of 636) with videos related to

Pageof 64
Sort By:
Hepatology (Baltimore, Md.)|December 9, 2014
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)Rohit Loomba, Claude B Sirlin, Brandon Ang, et al.
JAMA Network Open|June 26, 2023
Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related MortalityMara Sophie Vell, Rohit Loomba, Arunkumar Krishnan, et al.
Hepatology (Baltimore, Md.)|November 22, 2017
Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in micePhillipp Hartmann, Katrin Hochrath, Angela Horvath, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 8, 2022
Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysisDaniel Q Huang, Darren J H Tan, Cheng Han Ng, et al.
The Lancet. Oncology|March 7, 2022
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysisDarren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, et al.
The Journal of Clinical Investigation|June 20, 2017
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosisCyrielle Caussy, Meera Soni, Jeffrey Cui, et al.
Lancet (London, England)|December 4, 2014
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, et al.
Digestive Diseases (Basel, Switzerland)|September 13, 2023
Global Epidemiology of Cirrhosis: Changing Etiological Basis and Comparable Burden of Nonalcoholic Steatohepatitis between Males and FemalesDarren Tan, Kai En Chan, Zhen Yu Wong, et al.
JAMA Network Open|October 5, 2019
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver DiseaseDavid E Kleiner, Elizabeth M Brunt, Laura A Wilson, et al.
JAMA Network Open|June 29, 2022
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysisDarren Jun Hao Tan, Cheng Han Ng, Phoebe Wen Lin Tay, et al.
Pageof 64

Showing results (521-530 of 636) with videos related to

Sort By:
Pageof 64
Hepatology (Baltimore, Md.)|December 9, 2014
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)Rohit Loomba, Claude B Sirlin, Brandon Ang, et al.
JAMA Network Open|June 26, 2023
Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related MortalityMara Sophie Vell, Rohit Loomba, Arunkumar Krishnan, et al.
Hepatology (Baltimore, Md.)|November 22, 2017
Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in micePhillipp Hartmann, Katrin Hochrath, Angela Horvath, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 8, 2022
Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysisDaniel Q Huang, Darren J H Tan, Cheng Han Ng, et al.
The Lancet. Oncology|March 7, 2022
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysisDarren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, et al.
The Journal of Clinical Investigation|June 20, 2017
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosisCyrielle Caussy, Meera Soni, Jeffrey Cui, et al.
Lancet (London, England)|December 4, 2014
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, et al.
Digestive Diseases (Basel, Switzerland)|September 13, 2023
Global Epidemiology of Cirrhosis: Changing Etiological Basis and Comparable Burden of Nonalcoholic Steatohepatitis between Males and FemalesDarren Tan, Kai En Chan, Zhen Yu Wong, et al.
JAMA Network Open|October 5, 2019
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver DiseaseDavid E Kleiner, Elizabeth M Brunt, Laura A Wilson, et al.
JAMA Network Open|June 29, 2022
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysisDarren Jun Hao Tan, Cheng Han Ng, Phoebe Wen Lin Tay, et al.
Pageof 64